Cardiac Science soars on FDA clearance
This article was originally published in Clinica
Cardiac Science saw its share price leap last week after announcing that it had gained US clearance to sell the first fully-automatic public access defibrillator in its Powerheart product line.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?